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Candida bloodstream isolates (n  2,000) from two multicenter clinical trials carried out by the National
Institute of Allergy and Infectious Diseases Mycoses Study Group between 1995 and 1999 were tested against
amphotericin B (AMB), flucytosine (5FC), fluconazole (FLU), itraconazole (ITR), voriconazole (VOR),
posaconazole (POS), caspofungin (CFG), micafungin (MFG), and anidulafungin (AFG) using the NCCLS
M27-A2 microdilution method. All drugs were tested in the NCCLS-specified RPMI 1640 medium except for
AMB, which was tested in antibiotic medium 3. A sample of isolates was also tested in RPMI 1640 supple-
mented to 2% glucose and by using the diluent polyethylene glycol (PEG) in lieu of dimethyl sulfoxide for those
drugs insoluble in water. Glucose supplementation tended to elevate the MIC, whereas using PEG tended to
decrease the MIC. Trailing growth occurred frequently with azoles. Isolates were generally susceptible to AMB,
5FC, and FLU. Rates of resistance to ITR approached 20%. Although no established interpretative breakpoints
are available for the candins (CFG, MFG, and AFG) and the new azoles (VOR and POS), they all exhibited
excellent antifungal activity, even for those strains resistant to the other aforementioned agents.
Candidemia is now the fourth-most-common bloodstream
infection in the United States (11, 12, 23, 24). Antifungal
susceptibility testing has become an important tool in the man-
agement of patients with invasive candidiasis, since both in
vitro resistance and toxicity issues must be considered when
selecting an antifungal agent (5, 10, 15, 30, 33). The NCCLS
has developed the standardized and reproducible M27-A2
method for testing yeasts (18). This method is widely accepted
and readily available in reference centers and specialized clin-
ical laboratories. Although variations of this method have been
proposed and intense investigation into the effects of different
media and drug-solubilizing agents are ongoing, the basic
method has proven to be a useful and reproducible standard
(3, 4, 29, 36).
In this study, we examined the susceptibilities of 2,000
bloodstream Candida spp. isolates in the United States to
currently licensed and newly available antifungal agents. Since
small variations in the testing method have been shown to
potentially increase the correlation of in vitro results with clin-
ical response, three testing variations were studied: use of
antibiotic medium 3 for testing amphotericin B (AMB), sup-
plementation of the medium to 2% glucose (for all drugs), and
use of polyethylene glycol (PEG) as a solvent (for drugs that
are normally dissolved in dimethyl sulfoxide). (This work was
presented in part as abstracts 642 and 643 at the 39th Annual
Meeting of the Infectious Diseases Society of America, San
Francisco, Calif., 2001.)
MATERIALS AND METHODS
Isolates. The Mycoses Study Group (MSG) of the National Institutes of
Health carried out two clinical trials for patients with candidemia between 1995
and 1999 in the United States. MSG 33 was a study of fluconazole (FLU) plus
AMB versus FLU alone for the treatment of candidemia (32), and MSG 34 was
an epidemiological study (R. J. Hamill, P. G. Pappas, J. H. Rex, J. Y. Lee, H.
Horowitz, C. A. Kauffman, N. Hyslop, R. A. Larsen, D. K. Stein, E. A. Graviss,
C. J. Thomas, and the Mycosis Study Group, Abstr. 38th Annu. Meet. Infect. Dis.
Soc. Am., abstr. 36, 2000). The 39 participating centers shipped 2,947 Candida
isolates from 1,911 patients to the Laboratory of Mycology Research at the
University of Texas—Houston Medical School. Isolates were stored in sterile
water at room temperature, with a backup in glycerol frozen at 70°C. Since
some of the received isolates represented serial collection of isolates from a
single patient, subsequent work focused on the 2,000 isolates that represented
the first isolate of each species from each patient. Identification was carried out
using the API 20C AUX method (bioMerieux Vitek, Inc., Hazelwood, Mo.), with
supplemental standard morphological and biochemical testing for problem iso-
lates using cultures in cornmeal agar, germ tube testing, and the Murex identi-
fication system (Murex Diagnostics, Norcross, Ga.). Identification of an isolate as
C. dubliniensis was made based on (i) demonstration of absence of growth at
42°C, (ii) formation of abundant chlamydospores on cornmeal-Tween 80 agar,
(iii) absence of assimilation of xylose or -methyl-D-glucoside, (iv) DNA banding
patterns characteristic of a type isolate following digestion of genomic DNA, and
(v) amplification of a C. dubliniensis-specific 288-bp fragment (39).
Quality control isolates were used in every testing batch and included ATCC
750 (C. tropicalis), 5W31 (C. lusitaniae), ATCC 20019 (C. parapsilosis), ATCC
6258 (C. krusei), ATCC 90028 (C. albicans), and CL524 (C. lusitaniae). MICs for
these isolates were compared with published control limits (20, 35) and used to
guide quality control testing and validation per NCCLS guidelines (18).
Drugs. AMB, 5-flucocytosine (5FC), FLU, itraconazole (ITR), voriconazole
(VOR), posaconazole (POS), caspofungin (CFG), micafungin (MFG), and
anidulafungin (AFG) were obtained from their manufacturers as research pow-
ders and frozen (70°C) or refrigerated (3°C) as required. Drug stocks (100)
* Corresponding author. Mailing address: Division of Infectious
Diseases, University of Texas—Houston Medical School, 6431 Fannin
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were made following the NCCLS M27-A2 recommendations (18). AMB, ITR,
VOR, POS, and AFG were diluted in dimethyl sulfoxide. 5FC, FLU, CFG, and
MFG were diluted in deionized water. Additional testing was also carried out for
a limited number of randomly selected strains (15%) for ITR, VOR, and POS
in PEG 400 (Sigma, St. Louis, Mo.). All drug stocks were frozen at 70°C until
plate preparation. Testing ranges were 0.03 to 16 g/ml for all drugs, except for
5FC and FLU, which were tested at 0.13 to 64 g/ml.
Antifungal susceptibility testing. Antifungal susceptibility testing was carried
out following the NCCLS M27-A2 microdilution method (18). Briefly, isolates
were tested against all antifungal agents except AMB in RPMI 1640 (Sigma)
buffered with 0.075 M 3-(N-morpholino)propanesulfonic acid, pH adjusted to
7.0. Supplemental testing was carried out on randomly selected (15%) isolates
in 3-(N-morpholino)propanesulfonic acid-buffered RPMI 1640 supplemented
with glucose to 20 g/liter. AMB was tested in antibiotic medium 3 (Becton
Dickinson, Cockeysville, Md.) buffered with NAH2PO4 H20 plus NAHPO4, pH
adjusted to 7.0. Serial dilutions (2) of the antifungals in the appropriate me-
dium were performed, and 100 l of the dilutions was dispensed on microdilu-
tion plates (Corning, Corning, N.Y.). Plates were frozen at 70°C until used.
Validation of plate stability and potency was performed, running quality control
organisms with each batch of tests. After growth on Sabouraud dextrose agar
overnight, the fungal inocula were prepared as per M27-A2 to yield a 2
inoculum (1  103 to 5  103 CFU/ml), of which 100 l was dispensed in each
well of the microdilution plate for testing, resulting in the appropriate concen-
tration of medium, drug, and microorganisms in each well. The plates were
incubated at 35°C. MICs were assessed visually and by a spectrophotometer
reading at 570 nm after agitation at 24 and 48 h. MICs are defined as follows:
MIC-0 corresponds to the lowest drug concentration producing an optically clear
well or 95% reduction in optical density compared with medium only and MIC-2,
the lowest drug concentration producing prominent growth reduction or a 50%
reduction in optical density. This report focuses on spectrophotometer readings,
which were occasionally overridden by visual readings in cases of erroneous or
technically deficient spectrophotometric readings. Unless otherwise noted, the
MIC is the MIC-0 for AMB and MIC-2 for all other drugs. The choice of MIC-0
and antibiotic medium 3 for AMB is based on the fact that these testing condi-
tions appear to discriminate more-resistant isolates (36).
Statistical analysis. Descriptive statistics were performed using Microsoft
Excel and Access functions. r2 for regression analysis between azole congeners
was calculated using the log10 of the MICs with Epi Info 2002 software (Centers
for Disease Control and Prevention, Atlanta, Ga.).
RESULTS
NCCLS-M27-A2-based data by drug. Table 1 shows the
MICs at which 50% (MIC50) and 90% (MIC90) of the isolates
tested were inhibited for each drug at 24 h (AMB) or 48 h (all
other drugs) for the most commonly seen Candida spp. Table
2 shows MICs for the less frequent Candida spp. encountered
in the survey. Table 3 shows the frequency of drug-resistant
isolates identified in the survey for drugs that have established
NCCLS interpretative breakpoints. While limited in numbers,
the less commonly encountered Candida spp. showed uniform
susceptibility to all of the drugs and are not specifically dis-
cussed in the paragraphs below.
AMB. Based on the medium and endpoints chosen, resis-
tance to AMB appears to be rare. Using tentative breakpoints
suggested in previous work (6, 34), 2 to 3% of C. parapsilosis
and C. krusei isolates appeared to be resistant to this drug
(Table 3). Higher MICs were not seen for C. lusitaniae, a
species that is often, but not always, found to be resistant to
AMB (16).
5FC. More than 95% of isolates of all species except C.
krusei and C. tropicalis were susceptible to 5FC. Resistance to
5FC was noted for 12% of C. krusei isolates and 6% of C.
tropicalis isolates.
FLU. Susceptibility to FLU was similar to that seen in other
major surveillance surveys. C. krusei and C. glabrata showed
the highest MICs. Overall resistance to FLU occurred in less
than 10% of the tested strains. A separate analysis (data not
shown) of FLU resistance by year failed to show an increase in
resistance to FLU over the study years. Likewise, no regional
variations in resistance were seen among the participating cen-
ters.
ITR. As with FLU, the susceptibility patterns of ITR were
concordant with prior work. C. glabrata and C. krusei showed
high MICs. Complete resistance was seen in 18% of isolates
and thus was overall more common than for FLU.
POS. No interpretive breakpoints have been established for
this compound. Most isolates had low MICs (0.03 to 0.13
g/ml), with higher MICs noted for C. glabrata and C. krusei.
The MIC90 for C. tropicalis was increased due to the trailing
phenomenon (see below).
VOR. No interpretive breakpoints have been established.
MICs were mostly in the range of 0.03 to 0.25 g/ml. Higher
MICs were noted for C. krusei and C. glabrata. The MIC90 for
C. tropicalis was elevated due to trailing (see below).
AFG. There are no established interpretive breakpoints for
AFG. Most isolates exhibited MICs of 0.03 to 0.06 g/ml, but
C. parapsilosis strains showed MICs of 1 to 4 g/ml.
CFG. There are no established interpretive breakpoints for
caspofungin. Most isolates showed MICs of 0.5 to 2 g/ml, with
C. parapsilosis isolates tending to concentrate on the higher
end. Paradoxical fungal growth at the highest drug concentra-
tions, the so-called “Eagle” phenomenon, of unknown (but
unlikely) in vivo significance (8, 40, 41) and slight trailing were
occasionally observed when testing isolates with this drug.




AMB 5FC FLU ITR POS VOR AFG CFG MFG
50% 90% 50% 90% 50% 90% 50% 90% 50% 90% 50% 90% 50% 90% 50% 90% 50% 90%
C. albicans (733) 0.06 0.25 0.13 1 0.25 2 0.06 0.5 0.03 0.13 0.03 0.06 0.03 0.03 0.5 0.5 0.03 0.03
C. glabrata (458) 0.13 0.5 0.13 0.13 8 32 1 4 1 2 0.25 1 0.03 0.13 0.5 1 0.03 0.06
C. parapsilosis (391) 0.13 0.5 0.13 0.13 1 2 0.13 0.25 0.03 0.13 0.03 0.06 2 2 2 2 1 2
C. tropicalis (307) 0.13 0.5 0.13 0.5 0.5 16 0.13 1 0.06 1 0.06 2 0.03 0.13 0.5 1 0.03 0.06
C. krusei (50) 0.25 0.5 4 32 32 64 0.5 1 0.25 0.5 0.5 1 0.06 0.13 1 2 0.13 0.25
C. lusitaniae (20) 0.13 0.5 0.13 0.13 0.5 2 0.06 0.25 0.03 0.13 0.03 0.06 0.06 0.25 1 2 0.06 2
C. dubliniensis (18) 0.03 0.13 0.13 0.13 0.13 0.5 0.03 0.06 0.03 0.06 0.03 0.03 0.03 0.06 0.5 0.5 0.03 0.03
a Shown are the results for MIC-0 at 24 h for AMB and MIC-2 at 48 h for all other drugs. n, number of isolates.
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MFG. As with the other candins, interpretive breakpoints
are unknown, but most isolates exhibited MICs in the range of
0.03 to 0.06 g/ml, except for C. parapsilosis, which had MICs
of 0.5 to 4 g/ml. C. krusei and C. lusitaniae also tended to have
slightly higher MICs.
Cross-resistance. Cross-resistance among the azoles, partic-
ularly for pairs of congeners (FLU-VOR and ITR-POS), has
been a concern (22, 43, 44). Table 4 shows summaries for the
two combinations. As seen in Table 4, VOR MICs generally
correlated with FLU MICs, although some dispersion was seen
(r2  0.48). This correlation was much better for ITR and POS
(r2  0.65) (Table 4). The ultimate significance of these rela-
tionships remains to be determined.
Variations by testing media and drug solubilizing agent.
Table 5 shows MIC variations by testing medium and drug
solubilizing agent when compared to standard RPMI and rec-
ommended solvents for 344 isolates. In general, adding more
glucose to the medium tended to increase MICs of AFG and
CFG and decrease the MICs of FLU and VOR while it in-
creased those of ITR. Using PEG as a solvent decreased MICs
of azoles by one to two dilutions for30% of isolates, whether
glucose content was increased or not.
The trailing phenomenon. The trailing phenomenon is most
often encountered with azoles and is characterized by incom-
plete inhibition of growth (14, 31, 42). Severe trailing can be
identified by complete or partial growth inhibition at 24 h and
a partial growth inhibition at 48 h, with an elevated MIC. The
significance of this phenomenon and its impact on resistance
have been studied and do not appear to correlate with clinical
success or failure. Rather, trailing seems to be an artifact of the
method (2, 14, 42). This particularly applies to C. tropicalis,
which has a high frequency of trailing yet appears to be a
consistently azole-susceptible species. In contrast, C. glabrata
and C. krusei also show trailing, but they are truly known to be
less susceptible or resistant to azoles, thus adding to the evi-
dence that this phenomenon has no in vivo or clinical corre-
lation. The true nature, ramifications, and mechanisms of this
phenomenon are still under intense scrutiny. For this study, we
arbitrarily defined trailing growth as an eightfold increase in
MIC between 24- and 48-h results for any isolate. Table 6
shows the frequency of trailing for different drugs and Candida











































































































































































TABLE 3. Resistance rates for antifungals with published
interpretive breakpointsa
Species (n)
Frequency (%) of resistance to:
AMB 5FC FLU ITR
C. albicans (733) 0 3 5 8
C. glabrata (458) 0.8 0.2 8 51
C. parapsilosis (391) 2.5 2 2 4
C. tropicalis (307) 0.3 6 8 12
C. krusei (50) 2 12 34 20
C. lusitaniae (20) 0 0 0 0
C. dubliniensis (18) 0 0 0 0
Overall 0.8 3 6 18
a Resistance is defined as the following MICs (in micrograms per milliliter):
AMB, 1; 5FC, 32; FLU, 64; and ITR, 1. n, no. of isolates.
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all species except C. parapsilosis in the presence of azoles, and
for C. parapsilosis when examining candins.
DISCUSSION
We present antifungal susceptibility data for a large survey
of Candida spp. isolates causing bloodstream infections in the
United States between 1995 and 1999. Our results confirm data
from other surveys (21, 25, 27) and comprehensively present
data on currently available and/or new antifungal agents.
While species-specific variations and occasional resistance
were encountered, we can generally state that Candida spp.
were susceptible to the traditional standards of treatment for
primary infection: AMB and FLU. We found relatively low
levels of FLU resistance and no geographic or temporal vari-
ations, as opposed to the findings previously described by
Pfaller et al. (26). Resistance to ITR was found in nearly 20%
of strains, which is a proportion compatible with previously
published reports, and had species-specific trends. As shown in
several earlier papers, resistance to older azoles is most com-
monly demonstrated for C. krusei and C. glabrata (2, 3, 22–24,
37). The new azoles (POS and VOR) have encouraging and
potent antifungal activity against all Candida spp. including C.
glabrata and C. krusei. Early in vivo and clinical experiences
against infections caused by these organisms are encouraging
as well (1, 9, 19, 27, 38).
The candins, a new class of antifungal agent, seem to have
excellent in vitro activity against these organisms. It might be
important to note here that the interpretation of MICs for
these drugs is still a matter of some debate. Of note are the
TABLE 4. Cross-distribution of azole congener MICsa
Drug MIC (g/ml)
No. of isolates with MIC combination
VOR MIC (g/ml) POS MIC (g/ml)
0.03 0.06 0.13 0.25 0.5 1 2 4 8 16 16 0.03 0.06 0.13 0.25 0.5 1 2 4 8 16 16
FLU 0.13 191 5 1 1 1 1
0.25 368 15 3 2 2 2 1 5
0.5 293 53 9 3 3 2 1 1 1 1 3
1 182 46 26 5 3 2 3 1 4
2 60 27 20 5 3 1 1 2 3
4 14 30 43 25 4 4 1 1 1 2
8 6 15 55 66 35 5 4 1
16 2 3 8 25 48 35 2 1
32 3 2 4 21 15 27 5 1 1 2
64 5 4 13 3 9 2 1
64 14 2 2 1 3 9 7 16 11 2 17
ITR 0.03 374 17 1 1 1 1
0.06 296 160 29 5 3 2 1 2 1 1
0.13 116 109 27 10 6 1
0.25 24 76 52 31 17 6 1
0.5 8 23 17 59 109 42 8 3 1 2
1 3 2 5 7 50 80 23 3
2 7 2 3 4 10 23 28 4 2 4
4 1 2 1 1 2 20 17 2 1 3
8 1 2 2 2 1
16 1 2 2 2 1
16 4 1 2 5 6 4 12
a Distribution of VOR MICs by FLU MICs (r2  0.48) and POS MICs by ITR MICs (r2  0.65). All MICs are MIC-2 at 48 h.
TABLE 5. MIC variations by differences in test medium and solvent when compared to RPMI and standard solvent for 344
Candida spp. isolatesa
Drug
% of isolates for which result of MIC comparison applies in:






















AFG 48 50 2
CFG 51 30 18
FLU 54 1 42
5FC 83 1 16
ITR 28 57 14 52 0 43 60 6 34
POS 68 14 14 66 1 26 69 2 27
VOR 81 3 14 69 1 27 73 1 25
a Data are shown for MIC-2 at 48 h. GLU, glucose.
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relatively high MICs that were seen for C. parapsilosis. While
these MICs are comparatively higher than those for the other
species, there are no in vitro or in vivo data to suggest that this
represents resistance, and the achievable blood concentrations
of candins at the currently recommended doses generally equal
or slightly exceed these MICs (13). In fact, a recent study of
treatment of candidiasis with CFG versus AMB failed to show
significant variation in response rates by species (17). The
present survey also presents susceptibility data for less com-
mon Candida spp. While the numbers are limited, generally
good activity for most of the drugs was shown.
This survey also provides information on the performance
and reliability of the NCCLS M27-A2 method and its varia-
tions. Adding glucose to the medium tended to increase candin
and ITR MICs and decrease FLU MICs. Adding PEG as a
solvent tended to decrease MICs of ITR, POS, and VOR,
perhaps due to better solubility and delivery of the drug. Nev-
ertheless, the vast majority of MICs consistently remained
within two dilutions of the MIC obtained by the standard
NCCLS M27-A2 method.
The frequencies of the trailing phenomenon are consistent
with what has been previously reported (2). Our definition was
strict and very sensitive. It is also important to consider that
trailing isolates were not excluded from the resistance analysis;
thus, the true frequency of resistance may be slightly overesti-
mated. The nature of the trailing phenomenon is unknown, as
is its contribution to the perception of resistance in vitro and
the ultimate possibility of in vivo resistance translation (14, 31,
33, 36, 42).
Cross-resistance between the old and newer azoles deserves
further exploration. This phenomenon as been previously con-
sidered (28), and this study showed a proportional increase of
FLU-VOR and ITR-POS MICs, with r2 values of 0.48 and
0.65, respectively. While the MICs of the newer azole agents
are lower than achievable concentrations, the clinical signifi-
cance of these observations remains to be determined. Early
experience shows good in vivo and clinical activity of these two
new compounds against azole-resistant strains, classically
azole-resistant species like C. krusei, and species with dose-
dependent susceptibility like C. glabrata (7; L. Ostrosky-Zeich-
ner, A. M. L. Oude Lashof, B. J. Kullber, and J. H. Rex, Abstr.
40th Ann. Meet. Infect. Dis. Soc. Am., Abstr. 352, 2002).
While correlation with clinical outcomes is still needed to
validate the method for new drugs and establish interpretive
breakpoints, this study provides evidence of the reproducibility
and reliability of the NCCLS M27-A2 method and MIC trends
and patterns for these drugs.
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